N4 Pharma Plc

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BYW8QM32
GBP
0.01
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About N4 Pharma Plc stock-summary
stock-summary
N4 Pharma Plc
Pharmaceuticals & Biotechnology
N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B. Its vaccines include Nuvac and Nuvec. The Company is improving Sildenafil for erectile dysfunction. Sartans is a family of drugs known as Angiotensin II antagonists, including Losartan and Valsartan, commonly used for the treatment of hypertension. Aprepitant is an anti-emetic drug used in oncology. It is reformulating the existing Hepatitis B surface antigen vaccine (HBsAg), a sub unit vaccine. Nuvac is a nano-carrier delivery system for vaccines. Nuvec is an engineered silica nanoparticle, which has been designed for the intracellular delivery of large nucleic acids such as plasmid deoxyribonucleic acid and messenger ribonucleic acid.
Company Coordinates stock-summary
Company Details
Weston House, 1 Bradgate Park View , DERBY None : DE73 5UJ
stock-summary
Tel: 44 1332 690061
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Dr. John Chiplin
Non-Executive Chairman of the Board
Mr. Nigel Theobald
Chief Executive Officer, Executive Director
Dr. David Templeton
Executive Director
Dr. Christopher Britten
Non-Executive Director
Mr. Luke Cairns
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 5 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.98

stock-summary
Return on Equity

-60.49%

stock-summary
Price to Book

2.73